Open AccessA Perspective on Personalized Therapies in Hypertrophic Cardiomyopathy
Author(s) -
Paul H. Goldspink,
Chad M. Warren,
Jan Kitajewski,
Beata M. Wolska,
R. John Solaro
Publication year - 2021
Publication title -
journal of cardiovascular pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.762
H-Index - 100
eISSN - 1533-4023
pISSN - 0160-2446
DOI - 10.1097/fjc.0000000000000968
Subject(s) - hypertrophic cardiomyopathy , sarcomere , myofilament , medicine , mechanism (biology) , cardiomyopathy , cardiology , sudden cardiac death , bioinformatics , biology , heart failure , myocyte , philosophy , epistemology
A dominant mechanism of sudden cardiac death in the young is the progression of maladaptive responses to genes encoding proteins linked to hypertrophic cardiomyopathy. Most are mutant sarcomere proteins that trigger the progression by imposing a biophysical defect on the dynamics and levels of myofilament tension generation. We discuss approaches for personalized treatments that are indicated by recent advanced understanding of the progression.